For years, GLP-1 receptor agonists were primarily viewed as a narrow class of medications used to manage type 2 diabetes by improving blood glucose control and lowering A1c levels. However, a growing body of clinical trials, real-world evidence, and patient outcomes has revealed a much broader impact positioning these therapies as powerful tools for systemic metabolic improvement. Today, medications such as #Semaglutide (Ozempic, Wegovy) and #Tirzepatide (Mounjaro, Zepbound)

Get more benefits than just weightloss with Semaglutide and Tirzepatide!